The US Food and Drug Administration (FDA) today issued a proposal designed to assist companies focused on the development of new treatments for patients in the early stages of Alzheimer's disease (AD). "The scientific community and the FDA believe that it is critical to identify and study patients with very early Alzheimer's disease before there is too much irreversible injury to the brain," Russell Katz, MD, director of the Division of Neurology Products in the FDA's Center for Drug Evaluation and Research, said in a statement announcing the draft proposal. "It is in this population that most researchers believe that new drugs have the best chance of providing meaningful benefit to patients," he added. The guidance document outlines the FDA's current thinking about how best to identify and select patients with early AD, or those who are at risk of developing the disease, for enrollment in clinical trials, the FDA explains. The proposal ad